Heart gene therapy trial pulled before it even started

NCT ID NCT01002495

Terminated Disease control Sponsor: Helixmith Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study was designed to test the safety of a gene therapy called VM202 in people with chronic refractory myocardial ischemia—severe chest pain that doesn't improve with standard treatments. The therapy would be injected directly into the heart via a catheter. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VM202 (gene therapy)
What this could lead to: If successful, VM202 could offer a new way to reduce chest pain and improve blood flow in patients with severe, untreatable heart ischemia.
What could go wrong: This trial was withdrawn before any patients enrolled, so no data exists. Gene therapies carry risks like inflammation or arrhythmia, and earlier-stage results are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL ISCHEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Angina Pectoris Coronary Disease ischemic disease myocardial ischemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDIAL ISCHEMIA

Contacts and locations

Locations

Minneapolis Heart Institute Foundation/ Abbott Northwestern Hospital

Minneapolis, Minnesota, 55407, United States
Northwestern Memorial Hospital

Chicago, Illinois, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.